{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T12:05:49Z","timestamp":1794398749154,"version":"4.9.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015652","name":"Barts Charity","doi-asserted-by":"crossref","award":["MGU0365"],"award-info":[{"award-number":["MGU0365"]}],"id":[{"id":"10.13039\/100015652","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epstein-Barr Virus (EBV) is a ubiquitous gamma-herpesvirus with which ~\u200995% of the healthy population is infected. EBV infection has been implicated in a range of haematological malignancies and autoimmune diseases. Delayed primary EBV infection increases the risk of subsequent complications. Contemporaneous seroepidemiological data is needed to establish best approaches for successful vaccination strategies in the future.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a sero-epidemiological survey using serum samples from 2325 individuals between 0 and 25\u2009years old to assess prevalence of detectable anti-EBV antibodies. Second, we conducted a retrospective review of Hospital Episode Statistics to examine changes in Infectious Mononucleosis (IM) incidence over time. We then conducted a large case-control study of 6306 prevalent IM cases and 1,009,971 unmatched controls extracted from an East London GP database to determine exposures associated with IM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>1982\/2325 individuals (85.3%) were EBV seropositive. EBV seropositivity increased more rapidly in females than males during adolescence (age 10\u201315). Between 2002 and 2013, the incidence of IM (derived from hospital admissions data) increased. Exposures associated with an increased risk of IM were lower BMI, White ethnicity, and not smoking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We report that overall EBV seroprevalence in the UK appears to have increased, and that a sharp increase in EBV seropositivity is seen in adolescent females, but not males. The incidence of IM requiring hospitalisation is increasing. Exposures associated with prevalent IM in a diverse population include white ethnicity, lower BMI, and never-smoking, and these exposures interact with each other. Lastly, we provide pilot evidence suggesting that antibody responses to vaccine and commonly encountered pathogens do not appear to be diminished among EBV-seronegative individuals. Our findings could help to inform vaccine study designs in efforts to prevent IM and late complications of EBV infection, such as Multiple Sclerosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-020-09049-x","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T03:02:43Z","timestamp":1591930963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":185,"title":["Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom"],"prefix":"10.1186","volume":"20","author":[{"given":"Ashvin","family":"Kuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Meir","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"Vickaryous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Pakpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Middeldorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2993-585X","authenticated-orcid":false,"given":"Ruth","family":"Dobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"9049_CR1","doi-asserted-by":"crossref","unstructured":"Mentzer AJ, et al. Identification of host-pathogen-disease relationships using a scalable Multiplex Serology platform in UK Biobank. medRxiv. 2019;19004960.","DOI":"10.1101\/19004960"},{"key":"9049_CR2","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1038\/cti.2015.1","volume":"4","author":"HH Balfour Jr","year":"2015","unstructured":"Balfour HH Jr, Dunmire SK, Hogquist KA. Infectious mononucleosis. Clin Transl Immunology. 2015;4:e33.","journal-title":"Clin Transl Immunology"},{"key":"9049_CR3","doi-asserted-by":"publisher","first-page":"e64921","DOI":"10.1371\/journal.pone.0064921","volume":"8","author":"JB Dowd","year":"2013","unstructured":"Dowd JB, Palermo T, Brite J, McDade TW, Aiello A. Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6\u201319, 2003\u20132010. PLoS One. 2013;8:e64921.","journal-title":"PLoS One"},{"key":"9049_CR4","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1093\/infdis\/jit321","volume":"208","author":"HH Balfour Jr","year":"2013","unstructured":"Balfour HH Jr, et al. Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition. J Infect Dis. 2013;208:1286\u201393.","journal-title":"J Infect Dis"},{"key":"9049_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175574","volume":"12","author":"G Fourcade","year":"2017","unstructured":"Fourcade G, et al. Evolution of EBV seroprevalence and primary infection age in a French hospital and a city laboratory network, 2000-2016. PLoS One. 2017;12:e0175574.","journal-title":"PLoS One"},{"key":"9049_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1440-1827.2006.01936.x","volume":"56","author":"K Takeuchi","year":"2006","unstructured":"Takeuchi K, et al. Prevalence of Epstein--Barr virus in Japan: trends and future prediction. Pathol Int. 2006;56:112\u20136.","journal-title":"Pathol Int"},{"key":"9049_CR7","first-page":"135245852090790","volume":"23","author":"BM Jacobs","year":"2020","unstructured":"Jacobs BM, Giovannoni G, Cuzick J, Dobson R. Systematic review and meta-analysis of the association between Epstein-Barr virus, Multiple Sclerosis, and other risk factors. Mult Scler. 2020;23:1352458520907901 Online ahead of print.","journal-title":"Mult Scler"},{"key":"9049_CR8","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1001\/jama.286.24.3083","volume":"286","author":"A Ascherio","year":"2001","unstructured":"Ascherio A, et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA. 2001;286:3083\u20138.","journal-title":"JAMA"},{"key":"9049_CR9","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ana.21978","volume":"67","author":"LI Levin","year":"2010","unstructured":"Levin LI, Munger KL, O\u2019Reilly EJ, Falk KI, Ascherio A. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol. 2010;67:824\u201330.","journal-title":"Ann Neurol"},{"issue":"12","key":"9049_CR10","doi-asserted-by":"publisher","first-page":"e0226436","DOI":"10.1371\/journal.pone.0226436","volume":"14","author":"K Rostgaard","year":"2019","unstructured":"Rostgaard K, et al. Primary Epstein-Barr virus infection with and without infectious mononucleosis. PLoS One. 2019;14(12):e0226436.","journal-title":"PLoS One"},{"key":"9049_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1126\/scitranslmed.3002878","volume":"3","author":"J Cohen","year":"2011","unstructured":"Cohen J, et al. Epstein-Barr virus: an important Vaccine target for Cancer prevention. Sci Transl Med. 2011;3:107.","journal-title":"Sci Transl Med"},{"key":"9049_CR12","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1086\/523813","volume":"196","author":"EM Sokal","year":"2007","unstructured":"Sokal EM, et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis. 2007;196:1749\u201353.","journal-title":"J Infect Dis"},{"key":"9049_CR13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/978-981-10-7230-7_22","volume":"1045","author":"J Cohen","year":"2018","unstructured":"Cohen J, Vaccine I. Development for Epstein-Barr Virus. Adv Exp Med Biol. 2018;1045:477\u201393.","journal-title":"Adv Exp Med Biol"},{"key":"9049_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000318","volume":"4","author":"R Dobson","year":"2017","unstructured":"Dobson R, Kuhle J, Middeldorp J, Giovannoni G. Epstein-Barr-negative MS: a true phenomenon? Neurol Neuroimmunol Neuroinflamm. 2017;4:e318.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"9049_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10067-017-3873-5","volume":"37","author":"J Pakpoor","year":"2018","unstructured":"Pakpoor J, Goldacre R, Goldacre MJ. Associations between clinically diagnosed testicular hypofunction and systemic lupus erythematosus: a record linkage study. Clin Rheumatol. 2018;37:559\u201362.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"9049_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/ana.25688","volume":"87","author":"R Dobson","year":"2020","unstructured":"Dobson R, et al. Ethnic and socioeconomic associations with multiple sclerosis risk. Ann Neurol. 2020;87(4):599\u2013608.","journal-title":"Ann Neurol"},{"key":"9049_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/jmv.25338","volume":"91","author":"A Kourieh","year":"2019","unstructured":"Kourieh A, et al. Prevalence of human herpesviruses infections in nonmalignant tonsils: the SPLIT study. J Med Virol. 2019;91:687\u201397.","journal-title":"J Med Virol"},{"key":"9049_CR18","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/jmv.10132","volume":"67","author":"MC Morris","year":"2002","unstructured":"Morris MC, et al. Sero-epidemiological patterns of Epstein-Barr and herpes simplex (HSV-1 and HSV-2) viruses in England and Wales. J Med Virol. 2002;67:522\u20137.","journal-title":"J Med Virol"},{"key":"9049_CR19","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/ije\/dyu118","volume":"43","author":"K Rostgaard","year":"2014","unstructured":"Rostgaard K, et al. Sibship structure and risk of infectious mononucleosis: a population-based cohort study. Int J Epi. 2014;43:1607\u201314.","journal-title":"Int J Epi"},{"key":"9049_CR20","doi-asserted-by":"publisher","first-page":"9290","DOI":"10.1038\/s41598-019-45381-y","volume":"9","author":"L Gosc\u00e9","year":"2019","unstructured":"Gosc\u00e9 L, Winter JR, Taylor GS, Lewis JEA, Stagg HR. Modelling the dynamics of EBV transmission to inform a vaccine target product profile and future vaccination strategy. Sci Rep. 2019;9:9290.","journal-title":"Sci Rep"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-09049-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-020-09049-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-09049-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T09:19:34Z","timestamp":1723022374000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-020-09049-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9049"],"URL":"https:\/\/doi.org\/10.1186\/s12889-020-09049-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.01.21.20018317","asserted-by":"object"}]},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"3 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"UK Seroepidemiology Unit (SEU) sample analysis was covered by SEU ethical approvals which include consent for use in research (reference 05\/Q0505\/45); analysis of the EBV seronegative cohort was covered by internal ethical approval from VU University, Amsterdam. Primary and secondary care data analysis was performed on fully anonymised unlinked records and separate ethical approvals and additional consent were not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RD: Honoraria for speaking or other educational activities: Biogen, Merck, Teva. Support to attend educational meeting: Sanofi, Biogen, Teva. Honoraria for advisory board: Merck, Biogen. Research support: Biogen, Merck, Celgene.JM is CEO at Cyto-Barr BV.GG: I have received research grant support from Bayer-Schering Healthcare, Biogen-Idec, GW Pharma, Merck, Merck-Serono, Merz, Novartis, Teva and Sanofi-Aventis. I have also received personal compensation for participating on Advisory Boards in relation to clinical trial design, trial steering committees and data and safety monitoring committees from: Abbvie, Bayer-Schering Healthcare, Biogen-Idec, Canbex, Eisai, Elan, Fiveprime, Genzyme, Genentech, GSK, Ironwood, Merck, Merck-Serono, Novartis, Pfizer, Roche, Sanofi-Aventis, Synthon BV, Teva, UCB Pharma and Vertex Pharmaceuticals.JP: Served on an advisory board for Merck Serono. Associate Editor of BMC Public Health.BJ, NV, AK: none.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"912"}}